Completed PHASE2 INTERVENTIONAL 1-arm NCT02755857

Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis

A Single-arm, Multiple-Dose, Steady-State, Bioavailability Study With Twice Daily Dosing of Lozanoc™ (65 mg Itraconazole Capsules, Mayne) Taken Regardless of Food

Sponsor: Mayne Pharma International Pty Ltd

Conditions Neutropenia

Interventions Lozanoc

Updated 8 times since 2017 Last updated: Oct 24, 2018 Started: Jul 31, 2016 Primary completion: Dec 31, 2016 Completion: Jan 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Neutropenia and is currently completed. Mayne Pharma International Pty Ltd leads this study, which shows 8 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2018 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Aug 2018 — Nov 2018 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Aug 2018 [monthly]

Not Yet Recruiting PHASE2
Feb 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting PHASE2

First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayne Pharma International Pty Ltd

Data source: Mayne Pharma International Pty Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Darlinghurst, Australia